Table 1.
Baseline characteristics of 1003 adults with diabetes
| Characteristic | n (%) or mean (sd) |
| History of cancer | 126 (12.6%) |
| TZD therapy | 263 (26.2%) |
| Pioglitazone | 136 (51.3%) |
| Rosiglitazone | 128 (48.7%) |
| Any TZD alone | -71 (27.0%) |
| TZD and biguanide | -65 (24.7%) |
| TZD and sulfonylurea | -56 (21.3%) |
| TZD and biguanide and sulfonylurea | -71 (27.0%) |
| Gender: | |
| Men | 457 (45.6%) |
| Women | 546 (54.4%) |
| Age, years | 64.8 (12.0) |
| White ethnicity | 973 (97.3%) |
| Glycosolated hemoglobin A1C, % | 7.13 (1.3) |
| Insulin use | 185 (18.4%) |
| Body mass index, kg/m2 | 33.81 (7.4) |
| Alcohol use | 274 (27.4%) |
| Cigarette smoking | 170 (16.9%) |
| Median annual income, $ | 15000–29999 |
| Duration of diabetes, years | 10.2 (10.3) |
| High comorbidity | 495 (49.4%) |
| Number of prescription medications | 6.7 (3.8) |
| Number of anti-diabetic medications | 1.2 (0.9) |
| Physical functional status | 41.2 (12.4) |
| Mental functional status | 50.0 (10.7) |
TZD, thiazolidinedione; sd, standard deviation; n, number of subjects with the characteristic.